MedPath

Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

Phase 3
Conditions
Macular Degeneration
Registration Number
NCT00078221
Lead Sponsor
OccuLogix
Brief Summary

AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
180
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (8)

Retina Vitreous Associates

🇺🇸

Beverly Hills, California, United States

W. Bradley Kates, MD

🇨🇦

Oakville,, Ontario, Canada

Aran Eye Associates

🇺🇸

Coral Gables, Florida, United States

Retina Health Care

🇺🇸

Ft. Myers, Florida, United States

UIC Eye Center

🇺🇸

Chicago, Illinois, United States

Macula Care

🇺🇸

New York, New York, United States

Carolina Eye Associates

🇺🇸

Southern Pines, North Carolina, United States

Associated Retinal Consultants

🇺🇸

Bala Cynwyd, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath